The company’s EGFR and cMet targeted bispecific has generated early but encouraging signals in lung cancer – however, J&J faces stiff competition.
The company is one of very few to have studied combining PD-1 and PD-L1 blockade, an approach still in need of scientific validation.
Full data from the Checkmate-9ER trial suggest a new combo to match Merck & Co’s Keytruda plus Inlyta in first-line renal cancer.
Though late-breakers rightfully seize much of the limelight at the Esmo congress, investors should look further afield too.
Companies formed around unwanted big pharma assets have a mixed record, although some parents are better at finding spinouts than others.
The company’s deal with Dragonfly shows that disappointments have not eliminated interest in cytokine approaches.